Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

Allergopharma

Status and phase: Completed; Phase 4

Conditions: House Dust Mite Allergy

Treatments: Biological: House dust mite Novo Helisen Depot

Study type: Interventional

Funder types: Industry

Identifiers

NCT00263549

Al0201NH

Details and patient eligibility

About

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive skin prick test to house dust mite,
• Positive RAST test to house dust mite,
• Positive provocation test result to house dust mite,

Exclusion criteria

• Serious chronic diseases,
• Other perennial allergies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind